Key result
DOAC prescribing requires tailored clinical considerations in obesity, renal disease, cancer, and thrombophilia.
Answers are grounded in this paper and cite their sources.
Addresses prescribing considerations for direct oral anticoagulants in special patient populations including those with obesity, renal disease, cancer, or thrombophilia.
Prescribing DOACs with specific patient populations in mindWhat prescribing considerations should be top of mind when obesity, renal disease, cancer, or thrombophilia are at play?
No takes yet. Share an insight, caveat, or question.
Kevin Schleich (2023) studied this question. Direct oral anticoagulant (DOAC) prescribing requires specific clinical considerations in patient populations with obesity, renal disease, cancer, or thrombophilia.
Synapse has enriched 10 related papers. Consider them for comparative context: